Operator: Good day, and welcome to the Lexicon Pharmaceuticals Second Quarter 2023 Financial Results Conference Call. All participants will be in listen-only mode.
Lexicon Pharmaceuticals drug Inpefa is now FDA-approved for heart failure. Inpefa is third in its class, but the biotech says its pill can reach a specific subset of patients, enabling it to stand apart from rival medicines from AstraZeneca and partners Eli Lilly and Boehringer Ingelheim.